VYNE Therapeutics (VYNE) Stock Analysis & Winston Score

VYNE Therapeutics is a small biotechnology company focused on developing prescription drugs, primarily for skin conditions like acne and rosacea. Its most notable product was Amzeeq, a topical antibiotic foam for acne, along with Zilxi for rosacea — both sold to dermatologists and patients in the United States. The company has undergone significant restructuring, shifting its focus toward an early-stage pipeline targeting inflammation and immunology. VYNE generates revenue through drug sales and licensing agreements, though its current revenue base is very small following the sale of its commercial products to Journey Medical in 2022. It operates almost entirely in the U.S. and carries a near-zero market cap, reflecting deep financial losses and a negative operating margin that signals it spends far more than it earns. The central risk is whether its early-stage pipeline can produce viable drug candidates before the company exhausts its remaining cash resources.